創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
19/05/30 GEM072 Orally available somatostatin analogues Metabolic syndromes, acromegaly, hyperprolactinemia etc.* Oral Protein
Preclinical The technology and "know-how" to synthesize somatostatin analogues which will be more potent, more specific, stable and orally available have been established. A few analogues (at lead generation/optimization stage) with different combination of receptor selectivity and differential hormonal secretion inhibition properties are available.
*: Congenital hyperinsulinism, insulinomas, glucagonomas
問合せ
19/04/02 GEM071 Nanoparticl formulation of 2-deoxy-glucose Hepatocellular carcinoma, Renal cancer, Colorectal canser IV Small molecule
Preclinical In the xenograft model, the administration of nanoparticle formulation once a week showed superior antitumor effect than daily administration of 2-deoxyglucose alone. No side effects were observed.
Enhanced the antitumor effect by combination with existing anticancer drugs.
Enhanced T cell infiltration into tumor tissue.
The substrate used in the nanoparticle formulation are used in approved medicines (FDA).
問合せ
19/04/02 GEM070 Nanoparticl formulation of ɤ- Oryzanol Diabetes, hyperlipidemia, menopausal disorder, irritable bowel syndrome, etc. Oral Small molecule
Preclinical Improved intestinal absorption and shows a drug effect in an extremely small amount (1/1000 of normal particles).
Reduced preference for high fat diet.
Suppressed ER stress enhancement on hypothalamic/pancreatic islet.
Improved abnormal glucose metabolism and abnormal lipid metabolism.
The substrate used in the nanoparticle formulation are used in approved medicines (FDA).
問合せ
19/03/12 GEM024 1. Selective inducer of apoptosis through modulation of NF-kB/P53 axis. / 2. Eliciting adaptive immune response by recruitment of T Cells to tumors. Oral Squamous Cell Carcinoma see Note Small molecule
Phase 2 ready Updated on March 12, 2019

First-in-class, patented, combination therapeutic that simultaneously upregulates a cluster of genes promoting cell death and downregulates a cluster of genes promoting survival of cancer cells.
Phase 1 results showed no significant AE, dose-dependent modulation of key biomarkers involved in disease pathogenesis, and T cell recruitment to tumor making it “hot”.
FDA approved moving to Phase 2.

Route:Oral, pastille based topical delivery
問合せ
19/03/07 GEM069 Immuno-modulator (adjuvant) Vaccine, Please refer to Note Injection Other
Preclinical E.coli producing monophosphoryl Lipid A whose structure is similar to exsiting adjuvants such as MPL and GLA.
Shows similar efficacy with MPL in vitro and in vivo.
Lower cost production through simple fermetation and purification steps.

Indication:Vaccine, Cancer immunotherapy etc.
問合せ
19/03/01 GEM068 Gene therapy for novel target Lung and other cancers IV Nucleic acid
Preclinical The expression of this gene is reduced in various cancers.
Adenovirus expressing this gene inhibits the HIF-1α expression and proliferation of various cancer cells.
Adenovirus expressing this gene suppresses growth of lung cancer in nude mice.
問合せ
19/03/01 GEM067 c-Kit inhibitor Diabetic macular edema & Retinopathy Oral Small molecule
Phase 2a Inhibits stem cell factor-induced hyperpermeability
Reverses retinal vascular leakage in STZ-induced diabetic rats
Improved compliance to administration (oral) than anti-VEGF therapy (intra-vitreal injection)
Applicable to non-responders to anti-VEGF therapy
Repositioning of a marketed drug
問合せ
19/03/01 GEM066 Selective STAT3 inhibitor (DNA-based Decoy) Head and neck squamous cell carcinoma and non-small cell lung cancer [including exon 20 mutations] IV Nucleic acid
Pre-IND for systemic administration formulation 1st-in-class STAT3 decoy;
Suppresses binding of STAT3 to genomic DNA;
Inhibits proliferation and promotes apoptosis of many cancer cells;
Suppresses expression of STAT3 target genes and tumor growth in animal models;
Shows increased response in combination with cetuximab and also with PD-1;
Human Phase 0 study (intratumor injection); Suppresses STAT3 target genes expression with one dose
Does not affect normal oral keratinocytes;
Exploratory animal toxicology studies show no significant adverse effects;
問合せ
19/03/01 GEM064 Selective inhibitor of Nav channels Pain Oral Small molecule
Preclinical Potent and selective inhibitors for Nav 1.7/1.8 subtypes
Effective in inflammatory & neuropathic pain states
Exellent non-clinical ADMET profile
No off-target activity, very good in vitro cardiac safety margin, non-mutagenic
問合せ
19/02/12 GEM063 Novel 24hr ibuprofen patch Local pain in sprains Local Small molecule
Phase 1 completed High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove
Pre-clinical safety studies were completed 2017 with no concerns/issues
Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues
問合せ